Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Invasive|Hormone-receptor-positive Breast Cancer|HER2 Low Breast Carcinoma|Early-stage Breast Cancer
Interventions: DRUG: Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel|DRUG: Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.